Skip to main content
OpenTrials
Completed

NCT Number: NCT04752735

Endovascular treatmenT for Acute Ischemic Stroke in China

This is a retrospective real world registry study, aiming to explore the effectiveness and safety of endovascular treatment of acute ischemic stroke in a Chinese population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Endovascular Treatment Nervous System Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Neurology, General Hospital of Northern Theater Command

Shenyang, 110016, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: ≥ 18;
  • Ischemic stroke confirmed by head CT or MRI;
  • Patients receiving endovascular treatment;
  • First ever stroke or mRS≤2 after previous disease;
  • Complete and clear pre- and post-operative DSA images are available

Exclusion criteria

  • Imaging data not qualified for evaluation;
  • Absence of important clinical data;
  • The first 50 patients receiving endovascular treatment in a single centerr.

Treatment and study plan

Endovascular treatment

Other

all enrolled patients must receive endovascular treatment.

Primary outcomes

  1. Proportion of patients with modified Rankin Score (mRS) 0 to 2

    Time frame: Day 90

    the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome

Secondary outcomes

  1. Changes in National Institute of Health stroke scale (NIHSS)

    Time frame: Day 2, 7, 14

    the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome

  2. Proportion of patients with modified Rankin Score 0 to 2

    Time frame: Day180, 360

    Proportion of patients with modified Rankin Score 0 to 2

  3. Distribution of modified Rankin Score

    Time frame: Day 90, 180, 360

    Distribution of modified Rankin Score after treatment

  4. Proportion of symptomatic intracranial hemorrhage (sICH)

    Time frame: 48 hours

    sICH was defined as 4 or more increase in NIHSS caused by hemorrhage

  5. Proportion of intraparenchymal hemorrhage (PH1 and PH2)

    Time frame: 48 hours

    Proportion of intraparenchymal hemorrhage (PH1 and PH2) after treatment

  6. Proportion of death

    Time frame: Day 7

    death due to any cause

  7. Changes in cerebral edema

    Time frame: 48 hours, 7 days

    edema is determined by middle shift.

Sponsors and collaborators

Lead sponsor

General Hospital of Shenyang Military Region

Other

Registry information

Official study title

Endovascular treatmenT for Acute Ischemic Stroke in China: a Retrospective, National, Multi-center, Registry Study

Acronym: DETECT-China

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Feb 12, 2021
Registry last updated
Feb 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.